Journal article
Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study
K Harris, M Oshima, N Sattar, P Würtz, M Jun, P Welsh, P Hamet, S Harrap, N Poulter, J Chalmers, M Woodward
Diabetologia | SPRINGER | Published : 2020
Abstract
Aims/hypothesis: This biomarker study aimed to quantify the association of essential and other plasma fatty acid biomarkers with macrovascular disease, microvascular disease and death in individuals with type 2 diabetes. Methods: A case-cohort study (N = 3576), including 654 macrovascular events, 341 microvascular events and 631 deaths during 5 years of (median) follow-up, was undertaken as a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) study (full details of the study design and primary endpoints of the ADVANCE trial and its case-cohort have been published previously). This current study considers ..
View full abstractGrants
Awarded by Servier
Funding Acknowledgements
The biomarker work in the present study was funded by the Chest Heart and Stroke Association Scotland (R13/A149) and by the Glasgow Molecular Pathology Node, which is funded by the Medical Research Council and The Engineering and Physical Sciences Research Council (MR/N005813/1). The ADVANCE trial (ClinicalTrials.gov registration no. NCT00145925) was funded by the National Health and Medical Research Council (NHMRC) of Australia (project grant ID 211086 and program grant IDs 358395 and 571281) and by Servier. MO is supported by the Japan Society for the Promotion of Science Program for Fostering Globally Talented Researchers. MJ is supported by a Scientia fellowship from UNSW Sydney. MW is an NHMRC of Australia principal research fellow (1080206). The study sponsors were not involved in the design of the study, the collection, analysis, and interpretation of data, writing the report or the decision to submit the report for publication.